TransMedics Group Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 898

Employees

  • Stock Symbol
  • TMDX

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $85.25
  • (As of Friday Closing)

TransMedics Group General Information

Description

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 200 Minuteman Road
  • Suite 302
  • Andover, MA 01810
  • United States
+1 (978)
Primary Industry
Other Devices and Supplies
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 200 Minuteman Road
  • Suite 302
  • Andover, MA 01810
  • United States
+1 (978)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TransMedics Group Stock Performance

As of 20-Nov-2026, TransMedics Group’s stock price is $85.25. Its current market cap is $2.96B with 34.7M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$85.25 $94.02 $60.10 - $156.00 $2.96B 34.7M 926K $4.21

TransMedics Group Financials Summary

As of 30-Sep-2026, TransMedics Group has a trailing 12-month revenue of $728M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,288,686 4,210,482 2,280,613 2,665,424
Revenue 727,650 605,494 441,540 241,623
EBITDA 139,057 148,504 69,989 (7,680)
Net Income 144,453 190,291 35,464 (25,028)
Total Assets 1,517,937 1,068,373 804,076 706,047
Total Debt 866,902 519,278 518,287 515,946
Public Fundamental Data provided by Morningstar, Inc. disclaimer

TransMedics Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore TransMedics Group‘s full profile, request access.

Request a free trial

TransMedics Group Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore TransMedics Group‘s full profile, request access.

Request a free trial

TransMedics Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-sta
Other Devices and Supplies
Andover, MA
898 As of 2025

Latham, NY
 

Oxford, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TransMedics Group Competitors (24)

One of TransMedics Group’s 24 competitors is Angiodynamics, a Corporation company based in Latham, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Angiodynamics Corporation Latham, NY
OrganOx Formerly PE-Backed Oxford, United Kingdom
Organ Recovery Systems Formerly VC-backed Chicago, IL
Abiomed Corporate Backed or Acquired Danvers, MA
Lifetech Scientific Formerly VC-backed Shenzhen, China
You’re viewing 5 of 24 competitors. Get the full list »

TransMedics Group Patents

TransMedics Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260334461-A1 Apparatus and system for perfusing an ex-vivo lung without a gas exchange device Pending 25-Apr-2025
WO-2026226699-A1 Apparatus and system for perfusing an ex-vivo lung without a gas exchange device Pending 25-Apr-2025
US-20260334462-A1 Apparatuses for supporting an ex-vivo organ Pending 25-Apr-2025
WO-2026226716-A1 Apparatuses for supporting an ex-vivo organ Pending 25-Apr-2025
US-20260344659-A1 Compositions, methods, and devices for using ketone to preserve ex-vivo hearts Pending 25-Apr-2025 A01N1/143
To view TransMedics Group’s complete patent history, request access »

TransMedics Group Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TransMedics Group Investments & Acquisitions (4)

TransMedics Group’s most recent deal was a Merger/Acquisition with PAD Aviation Service. The deal was made on 06-Jul-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
PAD Aviation Service 06-Jul-2026 Merger/Acquisition Air
Summit Aviation (Air) 16-Aug-2023 Merger/Acquisition Air
Bridge to Life (Warm Perfusion EVOSS and Cold Perfusion LifeCradle Technologies) 02-Aug-2023 Corporate Asset Purchase Other Healthcare Technology Systems
Swissmed 01-Jan-2022 Merger/Acquisition Distributors (Healthcare)
To view TransMedics Group’s complete investments and acquisitions history, request access »

TransMedics Group ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

27 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Devices

Subindustry

of 209

Rank

Percentile

To view TransMedics Group’s complete esg history, request access »

TransMedics Group Affiliates

Subsidiaries (4)

Name Industry Location Year Founded
Northside Property Group Bozeman, MT 2023
PAD Aviation Service Buren, Germany 1996
Tmdx, Inc.2 Andover, MA
Transmedics, Inc.1 Andover, MA

TransMedics Group FAQs

  • When was TransMedics Group founded?

    TransMedics Group was founded in 1998.

  • Where is TransMedics Group headquartered?

    TransMedics Group is headquartered in Andover, MA.

  • What is the size of TransMedics Group?

    TransMedics Group has 898 total employees.

  • What industry is TransMedics Group in?

    TransMedics Group’s primary industry is Other Devices and Supplies.

  • Is TransMedics Group a private or public company?

    TransMedics Group is a Public company.

  • What is TransMedics Group’s stock symbol?

    The ticker symbol for TransMedics Group is TMDX.

  • What is the current stock price of TransMedics Group?

    As of 20-Nov-2026 the stock price of TransMedics Group is $85.25.

  • What is the current market cap of TransMedics Group?

    The current market capitalization of TransMedics Group is $2.96B.

  • What is TransMedics Group’s current revenue?

    The trailing twelve month revenue for TransMedics Group is $728M.

  • Who are TransMedics Group’s competitors?

    Angiodynamics, OrganOx, Organ Recovery Systems, Abiomed, and Lifetech Scientific are some of the 24 competitors of TransMedics Group.

  • What is TransMedics Group’s annual earnings per share (EPS)?

    TransMedics Group’s EPS for 12 months was $4.21.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process